Vaxcyte Inc (NASDAQ: PCVX)’s stock price has dropped by -3.71 in relation to previous closing price of 32.51. Nevertheless, the company has seen a loss of -2.87% in its stock price over the last five trading days. zacks.com reported 2025-04-01 that The decline in biotech stocks comes after FDA official Peter Marks’ resignation, citing irreconcilable differences with the new HHS Secretary.
Is It Worth Investing in Vaxcyte Inc (NASDAQ: PCVX) Right Now?
PCVX has 36-month beta value of 1.28. Analysts have mixed views on the stock, with 8 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for PCVX is 125.07M, and currently, short sellers hold a 10.08% ratio of that float. The average trading volume of PCVX on April 08, 2025 was 1.74M shares.
PCVX’s Market Performance
PCVX stock saw a decrease of -2.87% in the past week, with a monthly decline of -54.56% and a quarterly a decrease of -63.60%. The volatility ratio for the week is 12.91%, and the volatility levels for the last 30 days are 7.52% for Vaxcyte Inc (PCVX). The simple moving average for the past 20 days is -46.94% for PCVX’s stock, with a -64.36% simple moving average for the past 200 days.
Analysts’ Opinion of PCVX
Many brokerage firms have already submitted their reports for PCVX stocks, with Goldman repeating the rating for PCVX by listing it as a “Buy.” The predicted price for PCVX in the upcoming period, according to Goldman is $135 based on the research report published on December 20, 2024 of the previous year 2024.
Mizuho, on the other hand, stated in their research note that they expect to see PCVX reach a price target of $69. The rating they have provided for PCVX stocks is “Buy” according to the report published on December 07th, 2023.
PCVX Trading at -56.74% from the 50-Day Moving Average
After a stumble in the market that brought PCVX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -74.14% of loss for the given period.
Volatility was left at 7.52%, however, over the last 30 days, the volatility rate increased by 12.91%, as shares sank -54.72% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -65.21% lower at present.
During the last 5 trading sessions, PCVX fell by -1.86%, which changed the moving average for the period of 200-days by -56.53% in comparison to the 20-day moving average, which settled at $59.02. In addition, Vaxcyte Inc saw -61.76% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PCVX starting from Eydelman Mikhail, who sale 5,000 shares at the price of $70.74 back on Mar 05 ’25. After this action, Eydelman Mikhail now owns 41,620 shares of Vaxcyte Inc, valued at $353,699 using the latest closing price.
Eydelman Mikhail, the Officer of Vaxcyte Inc, proposed sale 5,000 shares at $68.87 during a trade that took place back on Mar 05 ’25, which means that Eydelman Mikhail is holding shares at $344,350 based on the most recent closing price.
Stock Fundamentals for PCVX
The total capital return value is set at -0.17. Equity return is now at value -20.41, with -18.78 for asset returns.
Based on Vaxcyte Inc (PCVX), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -6.37.
Currently, EBITDA for the company is -569.55 million with net debt to EBITDA at 0.69. The liquidity ratio also appears to be rather interesting for investors as it stands at 12.75.
Conclusion
To put it simply, Vaxcyte Inc (PCVX) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
